NCT02629393

Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

A Phase 2/3, Multicenter, Multinational, Open Label Study to Evaluate the Efficacy and Safety of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Origin Biosciences · Industry
• Sex: All
• Age: 1 Day – 5 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of ORGN001(formerly ALXN1101) in neonate patients with MoCD Type A

Conditions

• Molybdenum Cofactor Deficiency, Type A

Interventions

Type	Name	Description
DRUG	ORGN001 (formerly ALXN1101)

Timeline

• Start date: 2016-05-01
• Primary completion: 2022-09-01
• Completion: 2022-10-01
• First posted: 2015-12-14
• Last updated: 2023-10-17
• Results posted: 2023-10-17

Locations

11 sites across 6 countries: United States, Israel, Norway, Spain, Turkey (Türkiye), United Kingdom